Dahlia Ismail
- Pharmaceutical Science top 2%
- Advanced Drug Delivery Systems 5
- Ophthalmology top 2%
- Ocular Infections and Treatments 9
- Glaucoma and retinal disorders 4
- Immunology and Allergy top 5%
- Allergic Rhinitis and Sensitization 4
-
- Ocular Surface and Contact Lens 22
-
- Corneal Surgery and Treatments 16
-
- Urticaria and Related Conditions 2
-
- Dermatology and Skin Diseases 1
- Co-authors
- Mourad AmraneAndrea LeonardiChristophe BaudouinJean‐Sébastien GarrigueFrancisco C. FigueiredoGysbert van SettenSerge DoanMaite Sáinz de la Maza
In The Last Decade
Dahlia Ismail
20 papers receiving 567 citations
Peers
Comparison fields: 5 of 38
- Pharmaceutical Science 178
- Ophthalmology 259
- Immunology and Allergy 148
- Public Health, Environmental and Occupational Health 551
- Radiology, Nuclear Medicine and Imaging 223
Countries citing papers authored by Dahlia Ismail
This map shows the geographic impact of Dahlia Ismail's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dahlia Ismail with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dahlia Ismail more than expected).
Fields of papers citing papers by Dahlia Ismail
This network shows the impact of papers produced by Dahlia Ismail. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dahlia Ismail. The network helps show where Dahlia Ismail may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Dahlia Ismail, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 0 | |
| 2 | 2024 | 0 | |
| 3 | 2023 | 4 | |
| 4 | 2022 | 7 | |
| 5 | 2020 | 28 | |
| 6 | Safety and Tolerability of Topical Cyclosporine A Cationic Emulsion in Patients With Active Severe Vernal Keratoconjunctivitis (VKC) in Pediatric Patients: Pooled Results of the NOVATIVE and VEKTIS Trials | 2019 | 1 |
| 7 | 2019 | 27 | |
| 8 | 2018 | 39 | |
| 9 | 2018 | 73 | |
| 10 | 2018 | 17 | |
| 11 | 2018 | 18 | |
| 12 | Topical Ciclosporin A 1 mg/mL Cationic Emulsion in the Treatment of Active Severe Vernal Keratoconjunctivitis (VKC) in Pediatric Patients: Results of the Phase III VEKTIS Study | 2017 | 1 |
| 13 | 2017 | 37 | |
| 14 | 2017 | 68 | |
| 15 | Pooling of two randomized Phase III clinical trials of ciclosporin 1 mg/mL cationic emulsion (CsA CE) as a treatment for severe keratitis in patients with dry eye disease (DED) | 2016 | 1 |
| 16 | 2016 | 31 | |
| 17 | Topical ocular ciclosporin 1 mg/mL cationic emulsion in patients with dry eye with severe keratitis: Experience through the French early access program | 2016 | 2 |
| 18 | The Influence of Seasonality and Subtype in Vernal Keratoconjunctivitis (VKC) Patients in a Randomized Clinical Trial Investigating NOVA22007, a preservative-free cyclosporine cationic emulsion | 2012 | 1 |
| 19 | The Effect of Cyclokat® (preservative-free cyclosporine 0.1% cationic emulsion) on Dry Eye Disease Signs and Symptoms in Sjogren and non-Sjogren Patients with Moderate to Severe DED in a Phase III Randomized Clinical Trial | 2012 | 1 |
| 20 | Poor Correlation Between Dry Eye Disease (DED) Signs and Symptoms in a Phase III Randomized Clinical Trial | 2011 | 10 |
About Dahlia Ismail
Dahlia Ismail is a scholar working on Ophthalmology, Pharmaceutical Science and Public Health, Environmental and Occupational Health, having authored 22 papers that have together received 571 indexed citations. Recurring topics across this work include Ocular Surface and Contact Lens (22 papers), Corneal Surgery and Treatments (16 papers), Ocular Infections and Treatments (9 papers), Advanced Drug Delivery Systems (5 papers), Glaucoma and retinal disorders (4 papers), Allergic Rhinitis and Sensitization (4 papers), Urticaria and Related Conditions (2 papers) and Dermatology and Skin Diseases (1 paper). The work is most often cited by research in Pharmaceutical Science (178 citations), Ophthalmology (259 citations) and Immunology and Allergy (148 citations). Dahlia Ismail has collaborated with scholars based in France, Italy and Spain. Frequent co-authors include Mourad Amrane, Andrea Leonardi, Christophe Baudouin, Jean‐Sébastien Garrigue, Francisco C. Figueiredo, Gysbert van Setten, Serge Doan, Maite Sáinz de la Maza, Pasquale Aragona and János Németh. Their work appears in journals such as Ophthalmology, American Journal of Ophthalmology and Investigative Ophthalmology & Visual Science.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.